Canadian Public Health Association

Last updated
Canadian Public Health Association logo Canadian Public Health Association logo.jpg
Canadian Public Health Association logo

The Canadian Public Health Association (CPHA) is a national non-profit organization dedicated to public health.

Contents

The association was founded in 1910 by the editors of the Public Health Journal, which became the Canadian Public Health Journal under the auspices of the new organization. CPHA's objective was to establish professional standards for the field of public health and to advance research in the area. Prince Arthur, Duke of Connaught and Strathearn was named as the patron of the new organization, and its first president was T.A. Starkey of McGill University. CPHA received a federal charter in 1912. [1] The organization celebrated its centenary in 2010. [2]

The Association journal was later called the Canadian Journal of Public Health. [3] It is a member of the Committee on Publication Ethics (COPE). [4]

Associated Projects

Conferences

Canadian Immunization Conference

CPHA is a leading collaborating organization behind the annual Canadian Immunization Conference (CIC) alongside the Canadian Association for Immunization Research, Evaluation and Education (CAIRE), the Canadian Paediatric Society, and the Public Health Agency of Canada. [5] Sponsors for the event have included GlaxoSmithKline, Innovative Medicines Canada, Medicago, Merck, Pfizer, Public Health Ontario, Sanofi Pasteur, Seqirus and Valneva SE. [6] Notable presenters include Dr. Shelley Deeks, Chair of the National Advisory Committee on Immunization (NACI). [7]

Ontario Public Health Convention

CPHA co-hosts the annual Ontario Public Health Convention with the Association of Local Public Health Agencies (alPHa) and Public Health Ontario. [8]

CANVax

CPHA developed the Canadian Vaccination Evidence Resource and Exchange Centre (CANVax) with funding from the Public Health Agency of Canada through the Immunization Partnership Fund. [9] [10] CANVax is a member of the World Health Organization-led project Vaccine Safety Net. [11]

Funding

CPHA receives financial support from corporate partners including Seqirus and the Schulich School of Medicine & Dentistry at the University of Western Ontario. [12] Additional support has come from AstraZeneca, British Columbia Centre for Disease Control, Canadian Agency for Drugs and Technologies in Health, Canadian Institutes of Health Research (CIHR), Canadian Institute for Health Information (CIHI), Dalla Lana School of Public Health at the University of Toronto, Doctors of BC, GlaxoSmithKline, Heart and Stroke Foundation of Canada, Innovative Medicines Canada, Johnson & Johnson, Merck Canada, Novartis, Pfizer, Provincial Health Services Authority, Public Health Ontario, Sanofi Pasteur, University of Alberta School of Public Health, University of Waterloo Faculty of Applied Health Sciences, and Vancouver Coastal Health. [13] [14] [15] [16] [17] [18]

Related Research Articles

Health Canada is the department of the Government of Canada responsible for national health policy. The department itself is also responsible for numerous federal health-related agencies, including the Canadian Food Inspection Agency (CFIA) and the Public Health Agency of Canada (PHAC), among others. These organizations help to ensure compliance with federal law in a variety of healthcare, agricultural, and pharmaceutical activities. This responsibility also involves extensive collaboration with various other federal- and provincial-level organizations in order to ensure the safety of food, health, and pharmaceutical products—including the regulation of health research and pharmaceutical manufacturing/testing facilities.

<span class="mw-page-title-main">DPT vaccine</span> Combination vaccine

The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.

<span class="mw-page-title-main">Influenza vaccine</span> Vaccine against influenza

Influenza vaccines, colloquially known as flu shots, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. Vaccination against influenza began in the 1930s, with large-scale availability in the United States beginning in 1945.

<span class="mw-page-title-main">C. D. Howe Institute</span> Canadian non-profit policy research organization

The C. D. Howe Institute is a right-wing think tank in Toronto, Ontario, Canada. It aims to be distinguished by "research that is nonpartisan, evidence-based, and subject to definitive expert review." The institute's office is located in the Trader's Bank Building in downtown Toronto.

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccine.

<span class="mw-page-title-main">Canadian Paediatric Society</span> Canadian professional association

The Canadian Paediatric Society (CPS) is a national association of paediatricians.

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

<span class="mw-page-title-main">British Columbia Centre for Disease Control</span>

The BC Centre for Disease Control (BCCDC) is the public health arm for British Columbia's Provincial Health Services Authority.

<span class="mw-page-title-main">Hexavalent vaccine</span> Single vaccine protecting against six individual diseases

A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand.

Allison Joan McGeer is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.

<span class="mw-page-title-main">CoVLP</span> COVID-19 vaccine candidate produced in a plant

CoVLP was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.

<span class="mw-page-title-main">COVID-19 vaccination in Canada</span> COVID-19 vaccination programme in Canada

COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.

The National Advisory Committee on Immunization is an advisory body that provides the Government of Canada with medical and scientific advice relating to human immunization.

Dr. Shelley Deeks, MD, MHSc, FRCPC, FFAFPM, is a Canadian public health expert who is the chair of the National Advisory Committee on Immunization. Her advertised "specialities include communicable disease control, outbreak investigations, vaccine safety, epidemiology and program evaluation." She is a fellow of the Royal College of Physicians of Canada and the Australian Faculty of Public Health Medicine. Deeks was the executive lead in Ontario's COVID-19 pandemic response in 2020 in her role at Public Health Ontario.

<span class="mw-page-title-main">Caroline Quach-Thanh</span> Canadian pediatric microbiologist, epidemiologist and infectious diseases specialist

Caroline Quach-Thanh is a Canadian pediatric microbiologist, epidemiologist and infectious diseases specialist. She is a professor in the Université de Montréal Faculty of Medicine and Medical Lead in the Infection Prevention and Control Unit at CHU Sainte-Justine. She served as the Chair of the National Advisory Committee on Immunization (NACI) before and during the COVID-19 pandemic, and oversaw the approval process of COVID-19 vaccines in Canada.

<span class="mw-page-title-main">Innovative Medicines Canada</span> Association of pharmaceutical companies

Innovative Medicines Canada (IMC) is a national association of pharmaceutical companies that represents the interests of the research-based pharmaceutical industry in Canada. Its membership includes biopharmaceutical companies, vaccine developers, and manufacturers of medical devices, and works with government agencies, insurance companies, healthcare professionals and other stakeholders in the regulation and promotion of medicines.

<span class="mw-page-title-main">Pharmaceutical Advertising Advisory Board</span> Canadian not-for-profit organization

The Pharmaceutical Advertising Advisory Board (PAAB) is a Canadian not-for-profit organization based in Pickering, Ontario. Acting as a pseudo-regulatory body, PAAB offers review and pre-clearance services recognized by Health Canada to pharmaceutical companies and marketing agencies who wish to advertise directly to consumers and/or healthcare professionals. It is financed on a fee-for-service basis.

BIOTECanada, previously the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.

<span class="mw-page-title-main">19 to Zero</span> Canadian communications initiative

19 to Zero is a not-for-profit behavioural sciences initiative based in Calgary, Alberta, Canada. Hosted at the University of Calgary, the public–private partnership is made up of around 500 members including public health specialists, academics, behavioural psychologists, marketers and multimedia creators. Its purpose is to increase confidence in vaccines for COVID-19 and other diseases by tackling vaccine hesitancy. The group publishes materials on its website and through partner organizations, including videos, billboards, presentations, brochures and in-person events.

References

  1. Rutty, Christopher; Sullivan, Sue (2010). This is public health: a Canadian history. Canadian Public Health Association. p. 2.5. ISBN   978-1-894324-60-1.
  2. Picard, André (16 June 2010). "Cheers to a century of better public health in Canada". The Globe and Mail.
  3. "Canadian Journal of Public Health". Canadian Public Health Association. Archived from the original on 27 September 2016. Retrieved 17 September 2016.
  4. "Canadian Journal of Public Health". Springer. Retrieved 2022-03-18.
  5. "Collaborators | Canadian Public Health Association". www.cpha.ca. Retrieved 2022-03-20.
  6. "CIC 2018 Final Program" (PDF). Canadian Immunization Conference. 2018. Archived (PDF) from the original on 2022-03-20. Retrieved 2022-03-20.
  7. Public Health Agency of Canada (2022-02-25). "National Advisory Committee on Immunization (NACI): Membership and representation". Government of Canada. Archived from the original on 2022-03-19. Retrieved 2022-03-20.
  8. "The Ontario Public Health Convention". The Ontario Public Health Convention. Archived from the original on 2022-03-20. Retrieved 2022-03-20.
  9. "About CANVax". canvax.ca. Retrieved 2020-08-28.
  10. Public Health Agency of Canada (2022-10-12). "Immunization Partnership Fund". Government of Canada . Archived from the original on 2022-11-04. Retrieved 2022-11-04.
  11. "CANVax". Vaccine Safety Net. 2019-04-25. Retrieved 2020-08-28.
  12. "Corporate partners". Canadian Public Health Association. Archived from the original on 2021-12-08. Retrieved 2022-03-18.
  13. "2020 Annual Report" (PDF). Canadian Public Health Association. Archived (PDF) from the original on 2021-06-08. Retrieved 2022-03-18.
  14. "2019 Annual Report" (PDF). Canadian Public Health Association. Archived (PDF) from the original on 2021-06-08. Retrieved 2022-03-18.
  15. "2018 Annual Report" (PDF). Canadian Public Health Association. Archived (PDF) from the original on 2021-06-08. Retrieved 2022-03-18.
  16. "2017 Annual Report" (PDF). Canadian Public Health Association. Archived (PDF) from the original on 2021-06-08. Retrieved 2022-03-18.
  17. "2016 Annual Report" (PDF). Canadian Public Health Association. Archived (PDF) from the original on 2021-06-08. Retrieved 2022-03-18.
  18. "2015 Annual Report" (PDF). Canadian Public Health Association. Archived (PDF) from the original on 2021-06-08. Retrieved 2022-03-19.